Today: 29 April 2026
Browse Category

NYSE:REVG 30 October 2025 - 10 December 2025

Earnings to Watch Before and After the Bell on December 10, 2025: Oracle, Adobe, Synopsys, Chewy and More

Earnings to Watch Before and After the Bell on December 10, 2025: Oracle, Adobe, Synopsys, Chewy and More

Investors await the Federal Reserve’s decision and earnings from Oracle, Adobe, Synopsys, and Planet Labs, with markets volatile ahead of key AI results. Chewy, Uranium Energy, REV Group, Daktronics, VersaBank, and J. Jill report before the open. Chewy is expected to post a sharp year-on-year EPS swing. Options activity signals traders are bracing for large post-earnings moves in AI-linked stocks.
10 December 2025
···········

Stock Market Today

  • TSX Picks: Aecon Group, Savaria Among Undervalued Stocks with Upside Potential
    April 29, 2026, 9:24 AM EDT. Investors eye undervalued TSX stocks amid volatile fuel prices and steady interest rates. Aecon Group (TSX:ARE), a CA$3.36 billion construction firm, trades 24.8% below estimated fair value, boosted by rising Q1 sales and a strong project pipeline. Savaria Corporation (TSX:SIS), specializing in accessibility solutions with a CA$2.15 billion market cap, is down 32.2% against fair value. Both companies show promising earnings growth projections, potentially rewarding investors as market conditions stabilize. These stocks highlight opportunities found through cash flow-based valuation methods amid an uncertain economic backdrop.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop